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The aim of this study was to evaluate any possible
association of homocysteine with arterial stiffness
indices in patients with essential arterial hypertension
(AH), isolated office hypertension (IOH) and normoten-
sive controls. The final cohort comprised 231 normo-
tensives (NTs, 119 males), 480 patients with IOH (196
males) and 1188 patients with essential AH (713 males).
All patients were screened for plasma homocysteine
levels and lipidaemic profile and underwent aortic
compliance and wave reflection assessment by using
carotid-femoral pulse wave velocity (PWVc-f) and aortic
augmentation index corrected for heart rate (AIx)
accordingly. In the total population, stepwise multiple
linear regression analysis showed that homocysteine
levels remained a significant determinant of PWV (beta
(SE): 0.056 (0.007), Po0.001) and AIx (beta (SE): 0.236
(0.052), Po0.001) independently of the traditional fac-
tors affecting arterial stiffness and wave reflection.
When the three groups were examined separately,
homocysteine levels remained an independent determi-
nant of PWFc-f in all groups (NT: beta (SE): 0.070 (0.022),
P¼0.002; IOH: beta (SE): 0.109 (0.015), Po0.001; AH:
beta (SE): 0.040 (0.009), Po0.001). However, homocys-
teine levels remained an independent determinant of AIx
only in the IOH and AH, but not in the NT group (IOH:
beta (SE): 0.302 (0.124), P¼0.015; AH: beta (SE): 0.183
(0.057), P¼0.001; NT: beta (SE): 0.308 (0.240), P¼0.200).
This study points to an independent relationship
between circulating homocysteine levels, aortic compli-
ance and wave reflection.
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Introduction
Increased levels of plasma homocysteine have been
considered as an independent risk factor for cardi-
ovascular disease.
1,2 Specifically, high plasma
homocysteine levels are related to increased risk
for myocardial infarction, stroke, heart failure and
occlusive peripheral arterial disease.
3–7 Further-
more, hyperhomocysteinaemia is associated with
increased carotid intima-media thickness,
8 extracra-
nial carotid artery stenosis
9 and more advanced
atherosclerotic changes in coronary arteries.
10
Among the possible mechanisms that these effects
are exerted on are increased smooth muscle cell
proliferation,
11 endothelial dysfunction,
12 increased
collagen synthesis and deterioration of elastic
material of the arterial wall.
13
With regard to the relationship between homocys-
teine levels and hypertension, a synergistic effect of
these two parameters on cardiovascular risk
10,14 and
an independent relationship between high homocys-
teine levels and isolated systolic hypertension are
reported,
15 which was attributed to arterial stiffening.
Associations of homocysteine with cardiovascular
risk and with alterations in vascular properties have
led to studies of its association with arterial stiffness.
Thus, there are reports of a significant association
between plasma homocysteine pulse pressure
16 and
arterial pulse wave velocity (PWV);
17,18 however,
results are controversial as there are no reports of
such associations.
19
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www.nature.com/jhhOn account of this controversy in the earlier
reports, the purpose of this study was to assess the
relationship between plasma homocysteine levels,
arterial stiffness and wave reflection indices in
patients with arterial hypertension (AH), isolated
office hypertension (IOH) and normotensive con-
trols (NC).
Materials and methods
Study population
This retrospective study comprised 2150 patients
who visited our outpatient clinic from 2005 to 2008.
The study protocol has been approved by the Ethics
Committee of Hippokration Hospital. Patients with
acute and chronic inflammatory disease, endocrine
disorders, chronic obstructive pulmonary disease,
malignancy, renal insufficiency (serum creatinine
41.3mgdl
 1), heart failure, recent (o6 months)
cerebrovascular event, coronary artery disease,
history of stable/unstable angina or past myocardial
infraction, ventricular arrhythmia, sinus bradycar-
dia (o55b.p.m.), sinus tachycardia (4100b.p.m.) or
atrioventricular conduction defects, known diabetes
mellitus (earlier antidiabetic treatment) and any
condition preventing technically adequate ambula-
tory blood pressure (BP) monitoring were excluded
from the study.
Thus, the final cohort comprised 1899 patients,
of which 231 were normotensives (NT), 1188
presented with essential AH and 480 with IOH.
All participants were subjected to the following
procedures: physical examination, medical history,
repeated clinical BP measurement and blood sam-
pling for laboratory examinations. Patients with
borderline office BP and patients reporting normal
BP levels outside the clinic were subjected to 24-h
ambulatory BP monitoring.
BP measurements
The evaluation of BP was made according to the
2003 European Society of Hypertension/European
Society of Cardiology guidelines for adults.
20 BP was
measured three times with 1min intervals and with
the subject resting comfortably, back supported in
the sitting position after a 10–15min relax period.
A mercury sphygmomanometer was used for all
measurements with a medium- or a large-size cuff,
according to the subject’s arm circumference.
Furthermore, 40% of patients underwent ambula-
tory BP monitoring for 24h on the non-dominant
arm using a Spacelabs 90207 device (SpaceLabs Inc.,
Redmond, WA, USA). Technical details have been
reported earlier.
21
Anthropometric and biochemical measurements
For each subject, weight, height and waist to hip (W/
H) ratio were measured, and body mass index was
also calculated. Waist circumference was measured
at the midpoint between the bottom of the rib cage
and above the top of the iliac crest from patients at
minimal respiration to the nearest 0.1cm.
All subjects underwent full laboratory evaluation
(lipidaemic profile, liver and kidney function
indices). The blood samples were collected from
the antecubital vein between 8 a.m. and 10 a.m., in a
sitting position, after 12h of fasting and alcohol
absence. The biochemical evaluation was carried
out in the same laboratory that followed the criteria
of the World Health Organization Lipid Reference
Laboratories.
Plasma total homocysteine levels were deter-
mined using the homocysteine microplate enzyme
immunoassay assay (Bio-Rad Laboratories, Oslo,
Norway)
22 (cut-off points: 4–25mmol/l).
Measurements of arterial properties
Haemodynamic measurements were conducted in
the morning, in a quiet environment, at stable
temperature. Subjects were requested to abstain
from caffeine, smoking and alcohol for at least 12h
before arterial properties assessment was performed.
Systolic BP, diastolic BP and heart rate were
measured twice in both arms with automatic
mercury (Omron M4-I, CE 0197, Netherlands).
Aortic wave reflection assessment. We used
a validated, commercially available system
(SphygmoCor; AtCor Medical, Sydney, Australia),
which uses the principle of applanation tonometry
and appropriate acquisition and analysis software
for non-invasive recording and analysis of the
arterial pulse. First, from the radial artery record-
ings, the ensemble-averaged radial pressure wave-
form is obtained. Then, this is calibrated according
to sphygmomanometric systolic and diastolic BP
measured in the brachial artery (as there is practi-
cally negligible pressure pulse amplification
between the brachial and the radial artery; subse-
quently, the mean radial pressure is calculated by
digital integration of the waveform). Thereafter, from
the radial artery pressure waveform, the central
(aortic) arterial pressure waveform is derived.
Augmentation indices of the central waveform
were measured as indices of wave reflection.
Augmentation index was defined as augmented
pressure divided by pulse pressure and expressed
as a percentage. Augmentation index is a composite
measure of the magnitude of wave reflection and
arterial stiffness, which affects the timing of wave
reflection.
23 Larger values of augmentation index
indicate increased wave reflection from the periph-
ery and/or earlier return of the reflected wave as a
result of increased PWV (because of increased
arterial stiffness), and vice versa. To take into
account the potential effect of heart rate on aug-
mentation index, all values were automatically
corrected for heart rate by the sphygmocor software
augmentation index corrected for heart rate (AIx).
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Journal of Human HypertensionAortic stiffness assessment. The pulse travels at a
higher velocity in a stiff aorta and vice versa.
Carotid-femoral pulse wave velocity (PWVc-f) is a
well-established index of arterial elastic properties
and a prognosticator of cardiovascular risk. PWVc-f
was calculated from measurements of pulse transit
time and the distance travelled between two record-
ing sites (PWV¼distance (m)/transit time (s)) using a
validated non-invasive device (Complior; Dupont
Medical, Pantin, France), which allows online pulse
wave recording and automatic calculation of PWV.
24
Two different pulse waves were obtained simulta-
neously at two sites (at the base of the neck for the
common carotid and over the right-femoral artery)
with two transducers. The distance was defined as
(distance from the suprasternic notch to femoral
artery)—(distance from the carotid artery to the
suprasternic notch).
Statistical analysis. Data are presented as mean
±SEM except if differently indicated. Comparisons
between the baseline characteristics of the three
study groups (NC, IOH and AH) were performed
after analysis of variance. Nominal data were
compared by the w
2-test. The determinants of PWV
and augmentation index in the total population
were identified by using Pearson’s and Spearman’s
correlation coefficients for parametric and non-
parametric variables accordingly. The independent
determinants of PWVc-f and AIx in the total
population were identified by using stepwise multi-
ple linear regression analysis (dependent variables:
PWVc-f or AIx; independent variables tested: age,
gender, mean BP, body mass index, W/H, smoking
status, total cholesterol, high-density lipoprotein,
triglycerides, height, heart rate and homocysteine
levels). The independent determinants of PWVc-f
and AIx revealed by this analysis were used in two
multiple linear regression models to assess the
independent effect of the homocysteine levels on
PWVc-f (model 1) and AIx (model 2) separately for
each study group (NC, IOH and AH). Significance
was assumed at a two-tailed probability value of
o0.05.
Statistical analysis was performed using SPSS
package for Windows version 13.0 (SPSS, Chicago,
IL, USA).
Results
The baseline characteristics of the study population
according to the office and ambulatory BPs are
presented in Table 1. In the total population, both
PWVc-f and AIx presented significant linear rela-
tions with age, male gender, smoking, peripheral
systolic and diastolic BP, W/H ratio, smoking
intensity assessed by pack years, total cholesterol,
high-density lipoprotein and triglyceride levels
(Table 2). PWVc-f was additionally correlated with
body mass index and heart rate, which was not seen
with AIx, whereas the latter was significantly
associated with height (Table 2).
Finally, both PWVc-f and AIx were positively
associated with the plasma homocysteine levels as
shown in Table 2. In a stepwise multiple regression
analysis, the plasma homocysteine levels remained
a significant determinant of PWVc-f independent of
Table 1 Baseline characteristics of the study population according to the office and the ambulatory blood pressures
Normotensives Isolated office hypertension Arterial hypertension P
n (males) 231 (119) 480 (196) 1188 (713) o0.001
Age (years) 45.8±1.0 52.4±0.6 52.4±0.3 o0.001
Heart rate (bpm) 75.2±0.4 74.2±0.3 74.7±0.2 0.104
Waist (cm) 88.1±0.8 90.8±0.6 95.8±0.4 o0.001
Hip (cm) 103.1±0.6 105.2±0.4 106.9±0.3 o0.001
Waist/hip 0.85±0.005 0.86±0.004 0.89±0.002 o0.001
Body mass index (kgm
 2) 26.2±0.3 27.2±0.2 28.2±0.1 o0.001
Smokers (%) 37.7 36.7 41.2 0.192
Pack years 8.9±1.0 9.5±0.8 12.7±0.6 0.001
Total cholesterol (mgdl
 1) 199.5±2.5 211.1±1.7 210.7±1.1 o0.001
High-density lipoprotein (mgdl
 1) 52.2±0.8 54.1±0.6 50.1±0.4 o0.001
Triglycerides (mgdl
 1) 95.9±2.9 109.1±2.6 120.8±1.7 o0.001
Peripheral systolic BP (mmHg) 129.3±0.5 157.6±0.4 164.7±0.3 o0.001
Peripheral diastolic BP (mmHg) 82.0±0.3 97.8±0.3 100.9±0.2 o0.001
Peripheral pulse pressure (mmHg) 47.3±0.4 59.8±0.6 63.7±0.4 o0.001
Mean BP (mmHg) 97.8±0.3 117.7±0.2 122.2±0.2 o0.001
Aortic systolic BP (mmHg) 113.5±0.8 127.2±0.7 138.4±0.5 o0.001
Aortic diastolic BP (mmHg) 76.5±0.6 83.6±0.4 90.8±0.3 o0.001
Aortic pulse pressure (mmHg) 36.9±0.6 43.6±0.5 47.6±0.4 o0.001
Aortic augmentation index (%)
a 15.9±1.0 23.3±0.5 25.3±0.3 o0.001
Reflection wave time delay (ms) 145.8±1.2 138.9±0.6 137.4±0.3 o0.001
c-f pulse wave velocity (ms
 1) 6.46±0.08 7.23±0.05 8.05±0.04 o0.001
Homocysteine (mgdl
 1) 9.3±0.2 10.5±0.2 11.7±0.1 o0.001
Abbreviations: BP, blood pressure; c-f, carotid-femoral.
aCorrected for heart rate.
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density lipoprotein levels as shown in Table 3. In
accordance, the stepwise multiple linear regression
analysis also revealed an important association
between homocysteine levels and AIx independent
of other traditional factors affecting wave reflection,
such as age, gender, smoking status, height, mean
BP, body mass index, W/H ratio, heart rate and
triglyceride levels (Table 3). These findings argue for
a potential role of homocysteine in the remodelling
of the arterial wall leading to arterial stiffness and
enhanced wave reflection to the aorta.
When the three study groups were examined
separately, homocysteine levels remained a signifi-
cant independent determinant of PWVc-f in all
groups as shown in Table 4. However, AIx was
independently associated with the homocysteine
levels in the groups of IOH and AH, but not in the
NT group as shown in Table 4.
Discussion
The first finding of this study was that homocysteine
is an independent determinant of large artery
stiffness and wave reflections in the whole study
cohort. This finding argues for a potential role of
homocysteine in the remodelling of the arterial wall
leading to arterial stiffness and enhanced wave
reflection to the aorta. Earlier data suggest that
homocysteine levels are associated with aortic
stiffness in patients with type II diabetes mellitus.
25
In another study,
26 which involved health subjects,
such an association between Hcy levels and arterial
Table 2 Associations between demographic and haemodynamic variables with c-f pulse wave velocity and aortic augmentation index
corrected for heart rate in the total population
c-f pulse wave velocity Aortic augmentation index
a
Correlation coefficient P value Correlation coefficient P value
Age 0.425 o0.001 0.512 o0.001
Gender (male)
b 0.064 0.005  0.462 o0.001
Height  0.027 0.241  0.469 o0.001
Heart rate  0.102 o0.001  0.031 0.178
Peripheral systolic BP 0.446 o0.001 0.313 o0.001
Peripheral diastolic BP 0.127 o0.001 0.134 o0.001
Body mass index 0.169 o0.001  0.041 0.071
Waist/hip 0.255 o0.001  0.116 o0.001
Smoking
b 0.063 0.006 0.148 o0.001
Pack years 0.152 o0.001 0.214 o0.001
Total cholesterol 0.148 o0.001 0.234 o0.001
High-density lipoprotein  0.104 o0.001 0.198 o0.001
Triglycerides 0.160 o0.001 0.074 0.001
Homocysteine 0.333 o0.001 0.137 0.02
Abbreviations: BP, blood pressure; c-f, carotid-femoral.
aCorrected for heart rate.
bSpearman’s correlation.
Table 3 Independent determinants of c-f pulse wave velocity and aortic augmentation index corrected for heart rate in the total
population
c-f pulse wave velocity Aortic augmentation index
a
R
2¼0.319 R
2¼0.508
beta SE P beta SE P
Age 0.045 0.002 o0.001 Age 0.375 0.019 o0.001
Mean BP 0.036 0.003 o0.001 Mean BP 0.297 0.022 o0.001
Waist/hip 1.87 0.40 o0.001 Waist/hip 9.518 3.530 0.007
Homocysteine 0.056 0.007 o0.001 Homocysteine 0.236 0.052 o0.001
High-density lipoprotein  0.009 0.003 0.001 Smoking 4.312 0.410 o0.001
Males  7.025 0.670 o0.001
Height  0.250 0.031 o0.001
Body mass index  0.293 0.051 o0.001
Heart rate 0.138 0.035 o0.001
Triglyceride 0.009 0.004 0.014
Abbreviations: BP, blood pressure; c-f, carotid-femoral.
aCorrected for heart rate.
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clear controversy. The different results in the
literature can be explained by the fact that hyperho-
mocysteinaemia may interact with other cardiovas-
cular risk factors, namely, not only age and
hypertension, but also smoking or diabetes mellitus.
The possible mechanisms of the relationship
between Hcy and arterial stiffness are not yet fully
well established. However, it is known that elevated
Hcy levels induce oxidative injury to vascular
endothelial cells and impair the production of nitric
oxide, a strong relaxing factor by the endothe-
lium.
27,28 Increased Hcy levels also enhance platelet
adhesion to endothelial cells,
29 promote prolifera-
tion of vascular smooth muscle cells
30 and are
associated with higher levels of prothrombotic
factors, such as b-thromboglobulin, tissue plasmino-
gen activator and factor VIIc.
31 In addition, oral
folate supplementation is seen to improve the
arterial endothelium-dependent vascular function
of the brachial artery in healthy subjects with mildly
elevated levels of Hcy.
32 Furthermore, patients with
coronary artery disease and elevated Hcy, who were
administered folate and vitamin B12, improved
vascular endothelial function, as assessed by bra-
chial artery flow-mediated dilatation.
33
The second important finding of this study
was that Hcy was an independent determinant of
PWVc-f in healthy subjects as well as patients with
isolate office hypertension and essential hyperten-
sion. It has been earlier analysed that serum Hcy
levels enhance endothelial dysfunction. PWV is a
known marker of arterial distensibility and endothe-
lial function.
34 Although investigators have reported
a significant association between plasma Hcy with
pulse pressure
16 and arterial PWV in healthy sub-
jects and patients with essential hypertension,
17 no
such reports exist for patients with IOH. To our
knowledge, this is the first study reporting such an
association in white coat hypertensive patients.
Patients with IOH are reported to present with
impaired arterial distensibility, compared with NTs,
which entails a greater than normal cardiovascular
risk.
35 According to this study, Hcy levels pose an
additive burden to the cardiovascular profile of
patients with IOH, leading to large artery stiffening
independently of other factors.
Finally, this study revealed an independent
relationship of Hcy with AIx in patients with
essential hypertension and IOH, but not with NTs.
AIx is a measure of the contribution made by the
reflected pressure wave to the ascending aortic
pressure waveform,
36 and thus provides a measure
of systemic arterial stiffness.
37 Therefore, these data
show that Hcy levels are associated with systemic
arterial stiffness. The fact that this relation was not
noted in NT subjects may be explained by the fact
that AIx is a marker mainly of small artery stiffness,
and thus it can be assumed that Hcy does not affect
the arterial wall of small arteries in subjects with the
lack of additional risk factors. Furthermore, a
number of factors such as gender, heart rate, height,
smoking and lipidaemic profile are known to affect
AIx values,
38,39 which was also confirmed by the
present study results. It is possible that these factors
affect small artery stiffness to a greater extent in NT
patients than does Hcy. Finally, the small number of
participants in the NTs group may have affected the
results by underestimating the effect of Hcy on AIx.
There are some limitations in this study. First,
patients with masked hypertension were not in-
cluded, which could have led to interesting compar-
isons. Second, AIx measurement was made using
the methodology from reconstructed waveforms
using a transfer function, which has been criticized
and may, therefore, not detect changes in stiffness in
the small arteries. However, this is a large study
cohort that leads to strong and valid conclusions.
In conclusion, in hypertensive patients, patients
with IOH and NT subjects, there is a strong and
positive correlation of increased Hcy levels with
PWV. These results suggest that the evaluation of
aortic distensibility and Hcy levels can help in
cardiovascular risk assessment both in hypertensive
Table 4 Independent effects of plasma homocysteine levels on carotid-femoral pulse wave velocity and aortic augmentation index
corrected for heart rate separately for each study group according to the office and ambulatory blood pressures
Normotensives Isolated office hypertension Arterial hypertension
beta (SE) beta (SE) beta (SE)
c-f pulse wave velocity
Homocysteine
a 0.070 (0.022) 0.109 (0.015) 0.040 (0.009)
P 0.002 o0.001 o0.001
Aortic augmentation index
b
Homocysteine
c 0.308 (0.240) 0.302 (0.124) 0.183 (0.057)
P 0.200 0.015 0.001
Abbreviation: c-f, carotid-femoral.
aAfter adjustment for age, mean blood pressure, waist/hip and HDL levels.
bCorrected for heart rate.
cAfter adjustment for age, mean blood pressure, waist/hip, smoking status, gender, height, body mass index, heart rate and triglyceride levels.
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subjects. The contribution of arterial stiffness and
plasma Hcy measurements in risk assessment and
risk reduction strategies in such populations needs
to be confirmed by large prospective interventional
and observational studies.
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